We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+5.91%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$497M
AUM Growth
+$15.6M
Cap. Flow
+$142M
Cap. Flow %
28.52%
Top 10 Hldgs %
77%
Holding
31
New
11
Increased
2
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
ALLK
Allakos
ALLK
+$108M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$12.9M
3
RDUS
Radius Health, Inc.
RDUS
+$11.2M
4
LEGN icon
Legend Biotech
LEGN
+$10.1M
5
IMGN
Immunogen Inc
IMGN
+$9.32M

Top Sells

Rank Stock Value
1
APVO icon
Aptevo Therapeutics
APVO
+$27.2M
2
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$6.5M
3
CRVS icon
Corvus Pharmaceuticals
CRVS
+$2.51M
4
NXTC icon
NextCure
NXTC
+$2.02M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$1.84M

Sector Composition

Rank Sector Weight
1 Healthcare 93.65%
2 Financials 1.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
1
AnaptysBio
ANAB
$1.6B
$91.3M 18.37%
2,628,678
– –
HRTX icon
2
Heron Therapeutics
HRTX
$86.3M
$71.1M 14.29%
7,782,928
-124,159
-2% -$1.27M
RCKT icon
3
Rocket Pharmaceuticals
RCKT
$348M
$55.3M 11.12%
2,531,800
– –
LJPC
4
DELISTED
La Jolla Pharmaceutical Company
LJPC
$44.7M 8.99%
9,607,934
-441,290
-4% -$1.84M
ITOS
5
DELISTED
iTeos Therapeutics
ITOS
$43.6M 8.78%
937,500
+37,500
+4% +$1.25M
CCXI
6
DELISTED
ChemoCentryx, Inc.
CCXI
$18.2M 3.66%
500,000
– –
ODT
7
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$17.2M 3.47%
12,767,435
-2,747,131
-18% -$6.5M
ALT icon
8
Altimmune
ALT
$539M
$14.7M 2.95%
1,600,000
– –
ANIP icon
9
ANI Pharmaceuticals
ANIP
$1.77B
$13.8M 2.78%
+300,000
New +$12.9M
ALLK
10
DELISTED
Allakos
ALLK
$13M 2.61%
+1,323,393
New +$108M
IMGN
11
DELISTED
Immunogen Inc
IMGN
$11.1M 2.24%
+1,500,000
New +$9.32M
VINC
12
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$10.5M 2.11%
51,532
– –
CHRS icon
13
Coherus Oncology
CHRS
$217M
$10.4M 2.09%
650,000
– –
BLU
14
DELISTED
BELLUS Health Inc.
BLU
$9.66M 1.94%
+1,200,000
New +$7.96M
LEGN icon
15
Legend Biotech
LEGN
$4.3B
$9.32M 1.87%
+200,000
New +$10.1M
ATYR
16
aTyr Pharma
ATYR
$46.4M
$8.32M 1.67%
1,113,453
– –
CYPH
17
Cypherpunk Technologies Inc
CYPH
$66.2M
$8.1M 1.63%
250,000
– –
CRVS icon
18
Corvus Pharmaceuticals
CRVS
$1.1B
$7.47M 1.5%
3,101,709
-647,670
-17% -$2.51M
BCAB icon
19
BioAtla
BCAB
$5.59M
$5.85M 1.18%
+5,958
New +$7.62M
ONC
20
BeOne Medicines Ltd
ONC
$33.8B
$5.42M 1.09%
+20,000
New +$6.75M
RDUS
21
DELISTED
Radius Health, Inc.
RDUS
$5.29M 1.06%
+763,888
New +$11.2M
GNFT
22
DELISTED
Genfit
GNFT
$5.28M 1.06%
+1,055,994
New +$3.96M
TNGX icon
23
Tango Therapeutics
TNGX
$4.34B
$5.13M 1.03%
468,750
– –
RVPH
24
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$3.47M 0.7%
60,000
– –
CALT
25
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$2.48M 0.5%
+100,000
New +$2.01M
1
2

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $1.98B AUM 1.62% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return

Tang Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Tang Capital Management held 31 positions worth $497M, up 3.2% from $482M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Tang Capital Management deployed $142M of net new capital in Q4 2021, opening 11 new positions and adding to 2 existing holdings. Its largest new stake was Allakos: 1,323,393 shares worth $13M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Odonate Therapeutics, Inc. Common Stock, an estimated $6.5M trimmed.

  • Tang Capital Management's largest Q4 2021 buy was Allakos: 1,323,393 shares worth $13M.
  • Tang Capital Management added most to ASLAN Pharmaceuticals Limited American Depositary Shares in Q4 2021, an estimated $1.62M increase.
  • Tang Capital Management's biggest Q4 2021 reduction was Odonate Therapeutics, Inc. Common Stock, cutting an estimated $6.5M.
  • Tang Capital Management fully exited Aptevo Therapeutics in Q4 2021, selling an estimated $27.2M.
  • Tang Capital Management's ten largest holdings make up 77% of its $497M portfolio in Q4 2021.
  • Tang Capital Management opened 11 new positions and closed 2 in Q4 2021.
  • Tang Capital Management's portfolio value rose 3.2% quarter-over-quarter to $497M.

Based on Tang Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.